Background Improving the haemoglobin levels preoperatively leads to a reduction in
transfusions required. Intravenous iron III sucrose (IVI), with a good safety profile, represents …

Background Primary bacteraemia and bacteraemia caused by catheter infections entail a
high pharmaceutical cost. The 'Zero Bacteraemia Project'(BZP) for central intravenous …

Background Bendamustine is approved in Spain for the treatment of chronic lymphocytic
leukaemia (CLL), Non Hodgkin Lymphoma (NHL) and multiple myeloma (MM). The most …

Background Gefitinib is indicated for the treatment of locally advanced or metastatic non-
small cell lung cancer (NSCLC) with EGFR-TK activating mutations. Purpose To evaluate …

Background The recently marketed anti-diabetic drugs are considered new options without
great innovation. Purpose To determine the prescription profile and economic impact of …

Background Tacrolimus is a drug metabolised by CYP3A4. Since imatinib increases the
plasma concentrations of simvastatin, a CYP3A4 substrate, this indicates that it is an …

Background Gaucher disease is a hereditary metabolic disorder characterised by deficiency
of the lysosomal enzyme β-glucocerebrosidase which catalyses the hydrolysis of …

Background Conversion from intravenous (IV) to oral treatment has many advantages, such
as avoiding the adverse events attributed to IV treatment and using less costly drugs. It is …

Background Low therapeutic utility drugs (LTUDs) are those with controversial efficacy that
provide little improvement for the disease or the symptoms. These drugs have recently been …

Los ancianos son particularmente vulnerables a las reacciones adversas a medicamentos
(RAM), que, a su vez, se asocian con una morbimortalidad importante. Estas RAM en …